Cue vs En Carta Diagnostics
Cue vs En Carta Diagnostics, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Cue is on 35/100 and En Carta Diagnostics on 52/100.
Where each one leads
Cue
- domain rating: 54/100 against 0/100
- funding raised: $496M against $5.0M
En Carta Diagnostics
- our overall score: 52/100 against 35/100
At a glance
| Measure | Cue | En Carta Diagnostics |
|---|---|---|
| What it is | Cue is a health technology company developing and manufacturing a molecular diagnostic platform for rapid, lab-quality health testing at home. | Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity. |
| Category | Search, Search Engine, Mobile, HealthTech | Biotechnology, HealthTech, Diagnostics, Medical Devices |
| Sells toBusiness model | B2B | B2B2C |
| Offering | Software | Hardware |
| Founded | 2010 | 2022 |
| Headquarters | San Diego, United States | Paris, France |
| Status | Inactive | Inactive |
Size, funding and growth
| Measure | Cue | En Carta Diagnostics |
|---|---|---|
| Employees | Not published | 12 |
| Total funding | $496M | $5.0M |
| Latest round | Series C | Seed |
| LinkedIn followers | Not published | 2,091 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Cue | En Carta Diagnostics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 35/100 | 52/100 |
| Traction | 36/100 | 45/100 |
| Team | 30/100 | 70/100 |
| Community | 15/100 | Not published |
| Search visibility | 13/100 | 20/100 |
| Quality | 40/100 | 58/100 |
| Domain ratingLink authority, 0-100 | 54/100 | 0/100 |
Cue vs En Carta Diagnostics: common questions
Which is better, Cue or En Carta Diagnostics?
On our 0-100 score En Carta Diagnostics rates higher (52/100 against 35/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.
How do Cue and En Carta Diagnostics compare on the numbers?
Cue leads on domain rating (54/100 against 0/100), funding raised ($496M against $5.0M). En Carta Diagnostics leads on our overall score (52/100 against 35/100).
Read the full Cue review and pricing or the En Carta Diagnostics review and pricing. You can also browse other Cue alternatives we track.